Sign up for UnitedHealthcare Policy CS2026D00111S alerts
Get alerted when Policy CS2026D00111S changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs prior authorization and medical benefit coverage for healthcare-professional-administered FcRn blockers used primarily for generalized myasthenia gravis and, for Vyvgart Hytrulo, chronic inflammatory demyelinating polyneuropathy. It applies to UnitedHealthcare Community Plan members except where state-specific Medicaid policies or drug-code policies govern.
Policy Summary
PayerUnitedHealthcare
PolicyFcRn Blockers
Policy CodePolicy CS2026D00111S
Change TypeModified
Effective DateOctober 1, 2026
Next Review DateN/A
Key ActionSubmit prior authorization with documentation of the applicable diagnosis-specific criteria and treatment history.
The generalized myasthenia gravis serologic criterion was revised from requiring a positive anti-AChR antibody test to allowing positive anti-AChR, positive anti-MuSK, positive anti-LRP4, or triple-seronegative results.
For patients who are anti-AChR antibody positive, anti-LRP4 antibody positive, or triple seronegative, the treatment-failure pathway was revised to require either failure of at least two immunosuppressive agents over at least 12 months or failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.
A separate criterion was added for anti-MuSK antibody-positive patients requiring failure of at least one immunosuppressive agent over at least 12 months.
ICD-10 diagnosis code G70.0 was added to the applicable codes.
4FcRn blocker products addressed
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
12 months
Maximum authorization period
≥5Baseline MG-ADL requirement
≥2 pointsContinuation response
63 daysRystiggo cycle interval
G70.0ICD-10 code added
Coverage Criteria
Imaavy — Initial Therapy
Imaavy is covered for gMG when ALL of the following initial-therapy requirements are met:
ALL of the following
Submission of medical records confirming that the patient has not failed a previous course of Imaavy therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy.
MG-ADL total score ≥ 5 at initiation of therapy.
ONE of the following treatment-history pathways
If anti-AChR antibody positive
History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
Imaavy is dosed according to FDA-labeled dosing for gMG.
Prescribed by, or in consultation with, a neurologist.
Initial authorization is for no more than 12 months.
Imaavy — Continuation Therapy
Imaavy is covered for continuation therapy when ALL of the following requirements are met:
ALL of the following
Patient has previously been treated with Imaavy.
Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (IST) doses used before Imaavy.
Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
Rystiggo — Initial Therapy
Rystiggo is covered for gMG initial therapy when ALL of the following requirements are met:
ALL of the following
Submission of medical records confirming that the patient has not failed a previous course of Rystiggo therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
MGFA Clinical Classification of class II, III, or IV at initiation of therapy.
Rystiggo — Continuation Therapy
Rystiggo is covered for continuation therapy when ALL of the following requirements are met:
ALL of the following
Patient has previously been treated with Rystiggo.
Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of baseline IST doses used before Rystiggo.
Patient is not receiving Rystiggo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
Vyvgart or Vyvgart Hytrulo — Initial gMG Therapy
Vyvgart or Vyvgart Hytrulo is covered for gMG initial therapy when ALL of the following requirements are met:
ALL of the following
Submission of medical records confirming that the patient has not failed a previous course of Vyvgart therapy and has not failed a previous course of Vyvgart Hytrulo therapy.
Diagnosis of generalized myasthenia gravis (gMG).
ONE of the following serologic findings
Positive serologic test for anti-AChR antibodies.
Positive serologic test for anti-MuSK antibodies.
Positive serologic test for anti-LRP4 antibodies.
Vyvgart or Vyvgart Hytrulo — Initial gMG Treatment Requirements
The initial gMG request must also meet ALL applicable treatment-history requirements:
ALL of the following
ONE of the following treatment-history pathways
If anti-AChR, anti-LRP4, or triple seronegative
History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
Vyvgart or Vyvgart Hytrulo — Continuation gMG Therapy
Vyvgart or Vyvgart Hytrulo is covered for continuation of gMG therapy when ALL of the following requirements are met:
ALL of the following
Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
Reduction in signs and symptoms of myasthenia gravis.
Maintenance, reduction, or discontinuation of baseline IST doses used before starting Vyvgart or Vyvgart Hytrulo.
Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy or Rystiggo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
Vyvgart Hytrulo — Initial CIDP Therapy
Vyvgart Hytrulo is covered for initial CIDP therapy when ALL of the following requirements are met:
ALL of the following
Patient has not failed a previous course of Vyvgart Hytrulo therapy.
Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).
Progressive symptoms present for at least 2 months.
Symptomatic polyradiculoneuropathy indicated by progressive or relapsing motor or sensory impairment of more than one limb.
Initial CIDP therapy additionally requires ALL of the following treatment conditions:
ALL of the following
Trial and failure after a trial of at least 2 months, contraindication, or intolerance to corticosteroids.
ONE of the following immune-globulin pathways
Trial and failure after a trial of at least 3 months to an immune globulin (intravenous or subcutaneous).
ALL of the following
Intolerance to all immune globulins (intravenous or subcutaneous).
Dose has been adjusted or escalated to the maximally allowable and/or tolerated dose.
Vyvgart Hytrulo — Continuation CIDP Therapy
Vyvgart Hytrulo is covered for continuation of CIDP therapy when ALL of the following requirements are met:
ALL of the following
Patient has previously been treated with Vyvgart Hytrulo.
Documentation of positive clinical response to therapy measured by an objective scale (e.g., Rankin, Modified Rankin, or Medical Research Council [MRC] scale).
Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
Vyvgart Hytrulo is dosed according to FDA-labeled dosing for CIDP.
Prescribed by, or in consultation with, a neurologist.
Vyvgart Hytrulo — All Initial CIDP Conditions
All required conditions for initial Vyvgart Hytrulo therapy for CIDP must be satisfied:
ALL of the following
CIDP diagnosis is supported by progressive symptoms for at least 2 months and symptomatic polyradiculoneuropathy affecting more than one limb.
Electrodiagnostic findings are consistent with EFNS/PNS guidelines for definite CIDP, with at least one qualifying demyelinating parameter.
Corticosteroid therapy has failed after at least 2 months, or corticosteroids are contraindicated or not tolerated.
An applicable immune-globulin requirement is met: failure after at least 3 months, intolerance with maximally allowable and/or tolerated dose adjustment or escalation, or contraindication to all immune globulins.
Vyvgart Hytrulo is not combined with immune globulin and is administered according to FDA-labeled CIDP dosing by or in consultation with a neurologist.
Vyvgart Hytrulo — All Continuation CIDP Conditions
All required conditions for continuation Vyvgart Hytrulo therapy for CIDP must be satisfied:
ALL of the following
Patient has previously been treated with Vyvgart Hytrulo.
Positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or MRC scale.
Vyvgart Hytrulo is not combined with immune globulin.
Vyvgart Hytrulo is administered according to FDA-labeled CIDP dosing by or in consultation with a neurologist.
Reauthorization is for no more than 12 months.
CIDP Electrodiagnostic Criteria
Electrodiagnostic findings must be consistent with EFNS/PNS guidelines for definite CIDP. The following findings support demyelination:
At least one qualifying finding
Abnormal temporal dispersion: >30% duration increase between the proximal and distal negative-peak CMAP (at least 100% in the tibial nerve) in ≥2 nerves.
Distal CMAP duration prolongation in ≥1 nerve plus at least one other demyelinating parameter in ≥1 other nerve.
Low-frequency filter (LFF) 2 Hz F-wave latency above the applicable threshold: median >8.4 ms, ulnar >9.6 ms, peroneal >8.8 ms, or tibial >9.2 ms.
LFF 5 Hz F-wave latency above the applicable threshold: median >8.0 ms, ulnar >8.6 ms, peroneal >8.5 ms, or tibial >8.3 ms.
LFF 10 Hz F-wave latency above the applicable threshold: median >7.8 ms, ulnar >8.5 ms, peroneal >8.3 ms, or tibial >8.2 ms.
Vyvgart Hytrulo prefilled syringes for self-administered subcutaneous injection are obtained under the pharmacy benefit. The vial formulation for healthcare-professional administration is addressed under the medical benefit.
For gMG, Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo must not be used concurrently with CD19-directed cytolytic antibodies, complement inhibitors, other FcRn blockers, or immune globulin, as specified in the applicable criteria.
For CIDP, Vyvgart Hytrulo must not be administered in combination with an immune globulin.
For CIDP, Vyvgart Hytrulo must not be used in combination with immune globulin, including intravenous or subcutaneous immune globulin.
U.S. Food and Drug Administration (FDA) approval alone is not a basis for coverage. Coverage is determined by the applicable medical-necessity criteria in this policy.
Minimum classificationMGFA Clinical Classification class II, III, or IV
TimingAt initiation of therapy
Applies toGeneralized myasthenia gravis treatment with FcRn blockers
MG-ADL Continuation Response
Required responseAt least a 2-point improvement, meaning a reduction in MG-ADL score from pre-treatment baseline
Continuation evidenceReduction in signs and symptoms of myasthenia gravis
Provider Requirements and Denial Risks
Prior Authorization
Medical Benefit Prior Authorization Required
Submit a medical-benefit prior authorization request for covered FcRn blockers administered by a healthcare professional. Covered products include Imaavy IV, Rystiggo SC, Vyvgart IV, and Vyvgart Hytrulo vial SC; the Vyvgart Hytrulo prefilled syringe is obtained under the pharmacy benefit.
Medical-benefit products: Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo vial.
Obtain prior authorization for Vyvgart Hytrulo when treating CIDP. Initial and renewal authorizations are limited to no more than 12 months.
Applies to CIDP treatment with Vyvgart Hytrulo.
Initial authorization: no more than 12 months.
Reauthorization: no more than 12 months.
Policy Scope and Context
This policy addresses FcRn blockers administered by a healthcare professional for generalized myasthenia gravis, including Imaavy, Rystiggo, Vyvgart, and the Vyvgart Hytrulo vial. Vyvgart Hytrulo is also addressed for adult chronic inflammatory demyelinating polyneuropathy (CIDP) under specified criteria. Coverage requires clinically significant disease, applicable prior-treatment history, appropriate neurologist involvement, FDA-labeled dosing, and documented response for continued treatment. The self-administered Vyvgart Hytrulo prefilled syringe is obtained under the pharmacy benefit rather than this medical benefit policy.
Clinical Definitions and Scales
MGFA Clinical Classification
Qualifying classesClass II, III, or IV
ClassificationMyasthenia Gravis Foundation of America Clinical Classification
TimingClassification must apply at initiation of therapy
MG-ADL
ScaleMyasthenia Gravis Activities of Daily Living (MG-ADL)
Initiation thresholdTotal score of at least 5
TimingAt initiation of therapy
Initial Therapy Decision Criteria
Imaavy Initial Therapy – Complete Decision Tree
Covered when all initial-therapy criteria are met.
Imaavy initial therapy
Clinical eligibility: No previous Imaavy treatment failure; diagnosis of gMG; positive anti-AChR or anti-MuSK serologic test; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
Prior treatment pathway
Anti-AChR-positive pathway
Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
Continuation and Reauthorization Criteria
Imaavy Continuation – Prior Treatment, Response, and Ongoing Therapy
All continuation requirements must be met.
Imaavy continuation
Previously treated with Imaavy.
At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months
Rystiggo Continuation – Response, Combination, Interval, and Authorization
Required Prior Treatment Pathways
Step
Patient subgroup
Required prior therapy
Minimum duration / additional requirement
1
Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative generalized myasthenia gravis
Failure of at least two immunosuppressive agents
At least 12 months
1
Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative generalized myasthenia gravis
Failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin without symptom control
At least 12 months
1
Anti-MuSK-positive generalized myasthenia gravis
Failure of at least one immunosuppressive agent
At least 12 months
Step
Therapy sequence
Qualifying requirement
Duration / dose requirement
1
Corticosteroids
Trial and failure, or documented contraindication or intolerance
Trial of at least 2 months when used
1
Immune globulin after corticosteroids
Trial and failure; or intolerance to all immune globulins with dose adjustment or escalation to the maximally allowable and/or tolerated dose; or contraindication to all immune globulins
At least 3 months when trialed
Step
Required sequence
Qualifying pathway
Duration / additional requirement
1
Corticosteroids first
Trial and failure of corticosteroids
At least 2 months
1
Then immune globulin
Trial and failure of intravenous or subcutaneous immune globulin
At least 3 months
1
Then immune globulin
Intolerance to all immune globulins, with dose adjustment or escalation to the maximally allowable and/or tolerated dose
Maximally allowable and/or tolerated dose
1
Then immune globulin
Contraindication to all immune globulins
No trial duration specified
Administration and Benefit Channel
Billing Rule
Administer covered products in the office
Imaavy and Vyvgart are administered intravenously by a healthcare professional. Rystiggo and the Vyvgart Hytrulo vial are administered subcutaneously by a healthcare professional under the medical benefit.
Use the office-based medical benefit route for these healthcare-professional-administered presentations.
Billing Rule
Route the prefilled syringe through pharmacy
The Vyvgart Hytrulo prefilled syringe is self-administered subcutaneously and is obtained under the pharmacy benefit rather than the medical benefit.
Do not bill the self-administered prefilled syringe under the medical benefit policy.
Policy Summary
PayerUnitedHealthcare
PolicyFcRn Blockers
Policy CodePolicy CS2026D00111S
Change TypeModified
Effective DateOctober 1, 2026
Next Review DateN/A
Key ActionSubmit prior authorization with documentation of the applicable diagnosis-specific criteria and treatment history.
Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Imaavy is considered treatment failure.
Imaavy is dosed according to FDA-labeled dosing for gMG.
Prescribed by, or in consultation with, a neurologist.
Reauthorization is for no more than 12 months.
MG-ADL total score ≥ 5 at initiation of therapy.
ONE of the following treatment-history pathways
If anti-AChR antibody positive
History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Rystiggo is considered treatment failure.
Rystiggo is not given sooner than 63 days from the start of the previous treatment cycle.
Rystiggo is dosed according to FDA-labeled dosing for gMG.
Prescribed by, or in consultation with, a neurologist.
Reauthorization is for no more than 12 months.
Negative serologic tests for anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
MGFA Clinical Classification of class II, III, or IV at initiation of therapy.
MG-ADL total score ≥ 5 at initiation of therapy.
Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy or Rystiggo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
Vyvgart or Vyvgart Hytrulo is dosed according to FDA-labeled dosing for gMG.
Prescribed by, or in consultation with, a neurologist.
Initial authorization is for no more than 12 months.
Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Vyvgart or Vyvgart Hytrulo is considered treatment failure.
Reduction of motor conduction velocity in 2 nerves.
Prolongation of F-wave latency in 2 nerves.
Absence of F-waves in at least 1 nerve.
Partial motor conduction block of at least 1 motor nerve.
Abnormal temporal dispersion in at least 2 nerves.
Distal CMAP duration increase in at least 1 nerve.
Contraindication to all immune globulins (intravenous or subcutaneous).
Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
Vyvgart Hytrulo is dosed according to FDA-labeled dosing for CIDP.
Prescribed by, or in consultation with, a neurologist.
Initial authorization is for no more than 12 months.
Reauthorization is for no more than 12 months.
LFF 20 Hz F-wave latency above the applicable threshold: median >7.4 ms, ulnar >7.8 ms, peroneal >8.1 ms, or tibial >8.0 ms.
Baseline therapyMaintenance, reduction, or discontinuation of baseline immunosuppressive therapy
Rystiggo Treatment-Cycle Interval
Minimum interval63 days
Interval measured fromThe start of the previous Rystiggo treatment cycle
Coverage conditionRystiggo must not be administered sooner than this interval
Immunosuppressive-Agent Treatment History
Primary pathwayFailure of at least two immunosuppressive agents over at least 12 months
Alternative pathwayFailure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control
Anti-MuSK pathwayFailure of at least one immunosuppressive agent over at least 12 months
Example agentsAzathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate
CIDP Symptom Duration
Minimum durationAt least 2 months
Required clinical patternProgressive symptoms with symptomatic polyradiculoneuropathy
DistributionProgressive or relapsing motor or sensory impairment affecting more than one limb
CIDP Corticosteroid Trial
Minimum trial durationAt least 2 months
Required outcomeTrial and failure of corticosteroids
Alternative qualificationsA contraindication or intolerance to corticosteroids also qualifies
CIDP Immune Globulin Trial
Minimum trial durationAt least 3 months
Covered productsIntravenous immunoglobulin or subcutaneous immunoglobulin
Required outcomeTrial and failure of an immune globulin, unless a qualifying intolerance or contraindication pathway applies
Corticosteroid Trial
Minimum durationAt least 2 months
TherapyCorticosteroids
Qualifying alternativesContraindication or intolerance to corticosteroids
Immune Globulin Trial
Minimum durationAt least 3 months
TherapyIntravenous or subcutaneous immune globulin
Alternative pathwaysIntolerance to all immune globulins with maximally allowable or tolerated dose adjustment, or contraindication to all immune globulins
Initial Authorization
Authorization typeInitial authorization
Maximum durationNo more than 12 months
Applicable treatmentVyvgart Hytrulo for CIDP
Reauthorization
Authorization typeReauthorization
Maximum durationNo more than 12 months
Applicable treatmentVyvgart Hytrulo for CIDP continuation therapy
Motor Distal Latency Prolongation
ThresholdAt least 50% above the upper limit of normal (ULN)
Nerves requiredTwo nerves
FindingMotor distal latency prolongation
Motor Conduction Velocity Reduction
ThresholdAt least 30% below the lower limit of normal (LLN)
Nerves requiredTwo nerves
FindingReduction of motor conduction velocity
Abnormal Temporal Dispersion
Duration increaseMore than 30% between the proximal and distal negative peak CMAP
Nerves requiredAt least 2 nerves
Tibial nerve thresholdAt least 100% duration increase in the tibial nerve
CIDP Electrodiagnostic Criteria
Temporal dispersion pathwayMore than 30% duration increase between proximal and distal negative peak CMAP in at least 2 nerves, with at least 100% in the tibial nerve
Distal CMAP pathwayDistal CMAP duration prolongation in at least 1 nerve plus at least 1 other demyelinating parameter in at least 1 other nerve
Additional strongly supportive findingsMotor distal latency prolongation, reduced motor conduction velocity, F-wave abnormalities, absent F-waves, or motor conduction block as specified in the policy
Weak supportCriteria present in only one nerve are weakly supportive of demyelination
Low-frequency filter thresholdsThe policy specifies median, ulnar, peroneal, and tibial distal CMAP duration thresholds at 2, 5, 10, and 20 Hz
Step Therapy
Document Required gMG Treatment History
For gMG initial therapy, document the required prior-treatment failure history based on antibody status. AChR-positive, MuSK-positive, and applicable LRP4-positive or triple-seronegative patients have different immunosuppressive and rescue-therapy requirements.
AChR-positive, LRP4-positive, or triple-seronegative: failure of at least two immunosuppressive agents over at least 12 months, or failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.
MuSK-positive: failure of at least one immunosuppressive agent over at least 12 months.
Examples include azathioprine, corticosteroids, cyclosporine, methotrexate, and mycophenolate.
Step Therapy
CIDP Prerequisite Therapy
For CIDP initial therapy, document a trial and failure of corticosteroids after at least two months, unless corticosteroids are contraindicated or not tolerated. Also document the required immune-globulin prerequisite pathway.
Corticosteroid trial and failure: at least 2 months.
If corticosteroids are contraindicated or intolerable, document the applicable exception.
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: step_therapy
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: step_therapy
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: billing_rule
Unsupported block type: prior_auth
Unsupported block type: documentation
Unsupported block type: prior_auth
Note
FDA Approval Alone Does Not Establish Coverage
FDA approval alone does not establish coverage under this policy. Coverage remains subject to the policy criteria, benefit terms, applicable codes, and other governing requirements.
FDA indications are informational and do not guarantee reimbursement or claim payment.
Submit documentation meeting the applicable medical-necessity and authorization requirements.
Composition13-item grading system assessing muscle weakness
Item scoringEach item is scored from 0 to 3
Total range0 to 39
InterpretationHigher scores indicate more severe impairment
Typical CIDP
Weakness patternProgressive or relapsing, symmetric proximal and distal weakness of the upper and lower limbs
Sensory involvementSensory involvement of at least two limbs
DevelopmentDeveloping over at least 8 weeks
ReflexesAbsent or reduced tendon reflexes in all limbs
CIDP Variants
Recognized variantsDistal, multifocal, focal, motor, and sensory CIDP
Distal CIDPDistal sensory loss and muscle weakness predominantly in the lower limbs
Multifocal CIDPUsually asymmetric sensory loss and muscle weakness, upper-limb predominant, in more than one limb
Focal CIDPSensory loss and muscle weakness in only one limb
Motor or sensory CIDPMotor symptoms and signs without sensory involvement, or sensory symptoms and signs without motor involvement
Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
Administration requirements: No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months
Rystiggo Initial Therapy – Complete Decision Tree
Covered when all initial-therapy criteria are met.
Rystiggo initial therapy
Clinical eligibility: No previous Rystiggo treatment failure; diagnosis of gMG; positive anti-AChR or anti-MuSK serologic test; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
Prior treatment pathway
Anti-AChR-positive pathway
Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
Administration requirements: No prohibited combination therapy; treatment is administered no sooner than 63 days from the previous cycle start; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.≥63 days; authorization ≤12 months
Vyvgart or Vyvgart Hytrulo Initial gMG – Complete Decision Tree
Covered when all initial-therapy criteria are met.
Vyvgart or Vyvgart Hytrulo initial gMG therapy
Clinical eligibility: No previous treatment failure with the applicable product; diagnosis of gMG; positive anti-AChR, anti-MuSK, or anti-LRP4 serologic test, or triple-seronegative status; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
Prior treatment pathway
Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative pathway
ANY of the following
Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
Administration requirements: No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months
Vyvgart Hytrulo Initial CIDP – Complete Decision Tree
Covered when all initial CIDP criteria are met.
Vyvgart Hytrulo initial CIDP therapy
Diagnosis: No previous Vyvgart Hytrulo treatment failure; progressive CIDP symptoms for at least 2 months; symptomatic polyradiculoneuropathy with progressive or relapsing motor or sensory impairment of more than one limb; and qualifying electrodiagnostic findings consistent with definite CIDP.Symptoms ≥2 months
Corticosteroid requirement
Trial and failure after at least 2 months of corticosteroids.≥2 months
Contraindication or intolerance to corticosteroids.
Immune globulin requirement
Trial and failure after at least 3 months of intravenous or subcutaneous immune globulin.≥3 months
Intolerance to all immune globulins with escalation to the maximally allowable and/or tolerated dose.
Contraindication to all immune globulins.
Treatment and authorization: No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months
Vyvgart Hytrulo Initial CIDP Therapy – All Required Criteria
All of the following CIDP initial criteria must be met.
Initial CIDP criteria
Corticosteroid prerequisite: Trial and failure of corticosteroids after at least 2 months.≥2 months
Immune globulin prerequisite
Trial and failure of intravenous or subcutaneous immune globulin after at least 3 months.≥3 months
Intolerance to all immune globulins with dose adjustment or escalation to the maximally allowable and/or tolerated dose.
Contraindication to all immune globulins.
Other required conditions: No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months
Generalized Myasthenia Gravis Initial Therapy
The applicable serologic pathway and treatment-failure requirements must be met.
Revised gMG initial-therapy criteria
Permitted serologic results
Positive anti-AChR antibody test.
Positive anti-MuSK antibody test.
Positive anti-LRP4 antibody test.
Negative anti-AChR, anti-MuSK, and anti-LRP4 antibody tests (triple seronegative).
Treatment-failure pathway
Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative pathway
ANY of the following
Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
Failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
All continuation requirements must be met.
Rystiggo continuation
Previously treated with Rystiggo.
At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
No prohibited combination therapy; treatment cycles begin no sooner than 63 days from the prior cycle start; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.≥63 days between cycle starts; reauthorization ≤12 months
Vyvgart or Vyvgart Hytrulo Continuation for gMG
All continuation requirements must be met.
Vyvgart or Vyvgart Hytrulo continuation for gMG
Previously treated with Vyvgart or Vyvgart Hytrulo.
At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months
Vyvgart Hytrulo Continuation for CIDP – Decision Tree
All continuation requirements must be met.
Vyvgart Hytrulo continuation for CIDP
Previously treated with Vyvgart Hytrulo.
Positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or Medical Research Council scale.
No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months
Vyvgart Hytrulo Continuation – All CIDP Criteria
All CIDP continuation criteria must be met.
Continuation requirements
The patient has previously been treated with Vyvgart Hytrulo.
A positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or Medical Research Council scale.
The patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
Vyvgart Hytrulo is dosed according to FDA-labeled CIDP dosing.
Vyvgart Hytrulo is prescribed by or in consultation with a neurologist.
Reauthorization is for no more than 12 months.≤12 months